Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That Have Returned or Not Responded to Treatment (XenCART)

17 de noviembre de 2026 actualizado por: Cellogen Therapeutics Pvt. Ltd.

Phase I Clinical Trial of CD20/19 Chimeric Antigen Receptor CAR T Cells in Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia or Lymphoma

XenCART is an autologous bispecific CD20 and CD19 CAR T cell product from Cellogen Therapeutics Pvt Ltd. This first in human Phase I study at CMC Vellore will evaluate its safety tolerability and preliminary efficacy in adults with relapsed or refractory CD19 and CD20 positive B cell malignancies including B NHL and B ALL. Patients will undergo leukapheresis 9 to 12 day manufacturing fludarabine and cyclophosphamide lymphodepletion and a single intravenous infusion. The study includes a 28 day DLT evaluation period 24 months of active follow up and long term follow up thereafter. A 3 plus 3 dose escalation design with DSMB review after each cohort will evaluate sequential dose levels of 1 2 and 4 x 10 to the power 6 CAR T cells per kg to determine the recommended Phase II dose. Dual antigen targeting is expected to reduce CD19 negative relapse which is a major limitation of single target CAR T therapy. The study will establish the safety profile of XenCART and support its further development in India.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

18

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Dr Vikram Mathews, MBBS, MD, DM
  • Número de teléfono: 9003562033
  • Correo electrónico: vikram@cmcvellore.ac.in

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Tamil Nadu
      • Vellore, Tamil Nadu, India, 632012
        • Reclutamiento
        • Department of Haematology A Block 5th Floor Ranipet Campus Kilminnal Village Christian Medical College Vellore Ranipet Campus
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Dr Vikram Mathews, MBBS MD DM

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Subjects must meet ONE of the following

  1. Adults aged 18 to 65 years with relapsed or refractory CD19 and or CD20 positive B cell malignancy B ALL or B NHL
  2. B ALL At least 1 prior line of systemic therapy Ph positive ALL eligible after at least 1 BCR ABL1 TKI failure Morphological relapse with at least 5 percent blasts or MRD positive at least 10 to the power minus 4 by MFC eligible
  3. B NHL At least 2 prior lines including an anthracycline and an anti CD20 mAb At least 1 line if auto SCT ineligible or failed Transformed histologies require biopsy confirmation and prior therapy for the transformed component Refractory disease is defined as no response stable disease or progressive disease during or at the end of frontline immunochemotherapy such as R CHOP or similar OR early relapse within 3 to 12 months of end of treatment
  4. CD19 and or CD20 expression confirmed by IHC or flow cytometry on the most recent specimen within 6 months or at last relapse
  5. ECOG performance status 2 or less
  6. Adequate organ function bilirubin 1.5 times ULN or less AST ALT 3 times ULN or less creatinine 1.5 mg per dL or less or CrCl 50 mL per min or more ANC 1000 per microliter or more platelets 50000 per microliter or more LVEF 40 percent or more SpO2 92 percent or more on room air
  7. Adequate washout from prior therapy at least 2 weeks or 5 half lives whichever is shorter Anti CD20 mAb at least 4 weeks Checkpoint inhibitors at least 5 half lives
  8. Written informed consent with audio visual recording as per NDCT Rules 2019

Exclusion Criteria:

The presence of any of the following excludes enrollment

  1. Autologous SCT within 6 weeks of planned leukapheresis
  2. Prior allogeneic SCT any time
  3. Prior CAR T BiTE or other adoptive cell therapy unless CD19 or CD20 expression remains detectable on the most recent specimen
  4. Active CNS or meningeal disease prior CNS disease eligible if in remission 28 days with negative CSF
  5. Active second malignancy excluding adequately treated non melanoma skin cancer carcinoma in situ or any malignancy in CR 2 years
  6. Active HIV hepatitis B HBsAg positive hepatitis C HCV RNA detectable or tuberculosis infection
  7. Uncontrolled intercurrent illness NYHA III IV CHF LVEF less than 40 percent uncontrolled arrhythmia QTc greater than 480 ms active seizure disorder autoimmune disease on systemic immunosuppression uncontrolled hypertension or diabetes or active psychiatric illness precluding compliance
  8. Pregnancy or breastfeeding women of childbearing potential require negative beta hCG within 72 hours of leukapheresis and Day 0 infusion and effective contraception for 24 months post conditioning
  9. Active myelodysplastic syndrome therapy related MDS or therapy related AML
  10. Severe hypersensitivity to XenCAR T components lymphodepletion agents or to cilizumab not manageable with premedication

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Autologous bispecific CD20/CD19 CAR-T cells - 1 × 10⁶ cells/kg

Lymphodepletion, then a single IV infusion of XenCART at 1.0 × 10⁶ CAR-T cells/kg. n = 6 (3 B-ALL, 3 B-NHL).

All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 1 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

Experimental: Autologous bispecific CD20/CD19 CAR-T cells - 2 × 10⁶ cells/kg

Lymphodepletion, then a single IV infusion of XenCART at 2.0 × 10⁶ CAR-T cells/kg. n = 6 (3 B-ALL, 3 B-NHL).

All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 2 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

Experimental: Autologous bispecific CD20/CD19 CAR-T cells - 4 × 10⁶ cells/kg

Lymphodepletion, then a single IV infusion of XenCART at 4.0 × 10⁶ CAR-T cells/kg. n = 6 (3 B-ALL, 3 B-NHL).

All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 4 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of dose-limiting toxicities (DLT)
Periodo de tiempo: Day 0 (infusion) to Day +28

Number and percentage of participants experiencing at least one DLT, as defined in the protocol, at each dose level (unit: number of participants, %).

Day 0 (infusion) to Day +28
Incidence and maximum grade of cytokine release syndrome (CRS)
Periodo de tiempo: Day 0 to Day +28

Number and percentage of participants with CRS, by maximum grade per ASTCT 2019 consensus grading (unit: number of participants, %).

Day 0 to Day +28
Incidence and maximum grade of ICANS
Periodo de tiempo: Day 0 to Day +28

Number and percentage of participants with immune effector cell-associated neurotoxicity syndrome, by maximum grade per ASTCT 2019 consensus grading (unit: number of participants, %).

Day 0 to Day +28
Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Periodo de tiempo: Day 0 to Month 24

Number of participants with TEAEs/SAEs, graded by CTCAE (version as per protocol) (unit: number of participants).

Day 0 to Month 24
Maximum tolerated dose (MTD) / recommended Phase 2 dose (RP2D)
Periodo de tiempo: Day 0 to Day +28 of the last evaluable participant in each cohort

Highest XenCART dose level at which the DLT rate is acceptable per the dose-escalation rules, confirmed by DSMB (unit: CAR-T cells/kg).

Day 0 to Day +28 of the last evaluable participant in each cohort

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall response rate (ORR) in B-cell NHL
Periodo de tiempo: Day +28 and Day +90

Percentage of participants with complete or partial response per Lugano 2014 (PET-CT) (unit: %).

Day +28 and Day +90
Complete remission rate in B-ALL
Periodo de tiempo: Day +28 (±2)

Percentage of participants with CR/CRi by bone marrow morphology (unit: %).

Day +28 (±2)
MRD-negativity rate in B-ALL
Periodo de tiempo: Day +28 (±2)

Percentage of participants with MRD below 0.01% by multiparametric flow cytometry (unit: %).

Day +28 (±2)
Duration of response (DoR)
Periodo de tiempo: Up to Month 24

Time from first documented response to relapse, progression or death (unit: months).

Up to Month 24
Progression-free survival (PFS)
Periodo de tiempo: Up to Month 24

Time from infusion to progression, relapse or death from any cause (unit: months).

Up to Month 24

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Dr Vikram Mathews, Christian Medical College, Vellore, India

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

26 de octubre de 2026

Finalización primaria (Estimado)

14 de septiembre de 2028

Finalización del estudio (Estimado)

14 de septiembre de 2028

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

17 de noviembre de 2026

Publicado por primera vez (Actual)

19 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data (IPD) will not be shared publicly because the study involves a limited number of participants, and sharing individual-level data may pose risks to participant privacy and confidentiality. De-identified data may be considered for sharing upon reasonable request, subject to applicable ethical, regulatory, and data protection requirements.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir